SEOUL, South Korea--(BUSINESS WIRE)--Hanmi Pharmaceutical co., Ltd. (KSE:128940) will present the results of the phase I/II domestic clinical trial of HM61713 in patients with EGFR mutation positive non-small cell lung cancer at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2015, in Chicago, USA.
Help employers find you! Check out all the jobs and post your resume.
